Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab + venetoclax versus obinutuzumab + chlorambucil in previously untreated CLL with coexisting medical conditions
2023-504034-22-00Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2014
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 22
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Obinutuzumab + venetoclax with Obinutuzumab + chlorambucil (2 arms). Primary endpoint: Progression-free survival. Started Dec 2014; status: completed.
02
Drugs
obinutuzumabvenetoclaxchlorambucil
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2023-504034-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504034-22-00.